Perrigo Receives FDA Final Approval For Generic Equivalent To Prandin® - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

Perrigo Receives FDA Final Approval For Generic Equivalent To Prandin®

  • SPONSORED BY SOUTHEAST HEALTHMore>>

  • BJC changes charity care standards

    BJC changes charity care standards

    Sunday, April 20 2014 1:01 PM EDT2014-04-20 17:01:10 GMT
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
  • Clock ticking for states to adopt health exchanges

    Clock ticking for states to adopt health exchanges

    Friday, April 18 2014 2:39 PM EDT2014-04-18 18:39:20 GMT
    More than 30 states that defaulted to the federal government to run their health insurance markets under President Barack Obama's health care law must decide if they want to take a crack at it themselves. Time...
    More than 30 states that defaulted to the federal government to run their health insurance markets under President Barack Obama's health care law must decide if they want to take a crack at it themselves. Time is...
  • Blood test aims to predict breast cancer's return

    Blood test aims to predict breast cancer's return

    A new blood test may one day help predict the recurrence of breast cancer and also a woman's response to breast cancer treatment, researchers report.
    A new blood test may one day help predict the recurrence of breast cancer and also a woman's response to breast cancer treatment, researchers report.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Perrigo

DUBLIN, Jan. 24, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin® Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO)

Prandin® tablets (repaglinide tablets), are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of approximately $250 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This approval shows the talent and expertise of our R&D and regulatory affairs departments. This is another example of Perrigo's commitment to bring new products to market and deliver on our mission to provide quality, affordable healthcare to consumers."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri®. The Company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products™," and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2013, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.